NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY

Plexiform neurofibromas (PNs) can cause significant disfigurement, compression of vital structures, neurologic dysfunction, and pain. MEK pathway inhibition results in significant PN shrinkage in neurofibromatosis type 1 (NF1) mouse models of PN. We evaluated the efficacy of the MEK inhibitor, PD032...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Weiss, Brian, Plotkin, Scott, Widemann, Brigitte, Tonsgard, James, Blakeley, Jaishri, Allen, Jeffrey, Schorry, Elizabeth, Korf, Bruce, Rosser, Tena, Goldman, Stewart, Vinks, Alexander, Cutter, Gary, Dombi, Eva, Ratner, Nancy, Packer, Roger, Fisher, Michael
Format: Artigo
Language:Inglês
Published: Oxford University Press 2018
Subjects:
Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012484/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.514
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items